Monoclonal antibodies to epidermal growth factor receptor (EGFR) such as Cetuximab, are used to treat solid tumours but resistance to this treatment is a major clinical problem. It is essential to understand the mechanisms supporting the various forms of resistance to cetuximab in order to improve patient responses or to design novel anticancer drugs for additional therapy.

Compare and contrast these two papers (will be attached) with respect to their attempts to address this issue but also consider the following points:

Appropriate critical analysis (see guidance document on critical analysis)